A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
The prevalence of dementia in the Western world in people over the age of 60 has been estimated to be greater than 5%, about two-thirds of which are due to Alzheimer's disease. The age-specific prevalence of Alzheimer's disease nearly doubles every 5 years after age 65, leading to a prevalence of greater than 25% in those over the age of 90 (ref. 3). Here, to search for low-frequency variants in the amyloid-β precursor protein (APP) gene with a significant effect on the risk of Alzheimer's disease, we studied coding variants in APP in a set of whole-genome sequence data from 1,795 Icelanders. We found a coding mutation (A673T) in the APP gene that protects against Alzheimer's disease and cognitive decline in the elderly without Alzheimer's disease. This substitution is adjacent to the aspartyl protease β-site in APP, and results in an approximately 40% reduction in the formation of amyloidogenic peptides in vitro. The strong protective effect of the A673T substitution against Alzheimer's disease provides proof of principle for the hypothesis that reducing the β-cleavage of APP may protect against the disease. Furthermore, as the A673T allele also protects against cognitive decline in the elderly without Alzheimer's disease, the two may be mediated through the same or similar mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nearly 30 LOAD susceptibility loci2-12 are known, and risk is significantly polygenic13.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“Recent sequencing studies identified a number of genes that have rare variants associated with AD9-11,18-24.”
From Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) · cites this paper as [10]
In the citing paper
“The NH2-terminal APP A673T(Icelandic) mutation, however, makes APP a less favorable substrate for 𝛃 -secretase, resulting in decreased A 𝛃 production (299).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [299]
In the citing paper
“This observation is also true for the rare variant p.A673T (rs63750847) in APP, which was identified in Icelanders and was shown to have a strong protective effect against age-related cognitive decline as well as AD [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
In the citing paper
“The p.A673T variant was observed in control subjects aged over 85 years at a frequency of 0.45%, which is higher than that seen in AD patients [43].”
From Genetics of Alzheimer’s disease: An East Asian perspective (2023) · cites this paper as [43]
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
A new multipoint method for genome-wide association studies by imputation of genotypes
Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007) · Nature Genetics · doi:10.1038/ng2088 · Cited by 2,609
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932
MDS Cognitive Performance Scale(C)
Morris, J. N., Fries, B. E., Mehr, D. R., Hawes, C., Phillips, C., Mor, V., & Lipsitz, L. A. (1994) · Journal of Gerontology · doi:10.1093/geronj/49.4.m174 · Cited by 1,810
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Purification and cloning of amyloid precursor protein β-secretase from human brain
Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., et al. (1999) · Nature · doi:10.1038/990114 · Cited by 1,612
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashler, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., et al. (1999) · Nature · doi:10.1038/990107 · Cited by 1,438
Cited by
Items 101–200 of 1,008
Genes associated with Alzheimer's disease: an overview and current status
Giri, M., Lü, Y., & Zhang, M. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s105769 · Cited by 311
Alexander, A. G., Marfil, V., & Li, C. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00279 · Cited by 310
“By contrast, a recently identified mutation in APP affects cleavage of APP, causing less Aβ production and conferring neuroprotective benefits (Jonsson et al., 2012).”
BackgroundAmyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
Villegas, S., Roda, A., Serra-Mir, G., Montoliu-Gaya, L., & Tiessler, L. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.332127 · Cited by 306
“In contrast, Icelandic mutation (A673T), located at the β-site as well, lessens amyloidogenic APP processing and so protects against AD onset (Jonsson et al., 2012).”
BackgroundSuspected non-Alzheimer disease pathophysiology — concept and controversy
Jack, C. R., Knopman, D. S., Chételat, G., Dickson, D., Fagan, A. M., Frisoni, G. B., Jagust, W., Mormino, E. C., Petersen, R. C., Sperling, R. A., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.251 · Cited by 306
The neuroimmune axis of Alzheimer’s disease
Jorfi, M., Maaser-Hecker, A., & Tanzi, R. E. (2023) · Genome Medicine · doi:10.1186/s13073-023-01155-w · Cited by 292
“…al., 2013 [122] 21 ADAMTS1 Immunomodulator Rodríguez‑Baena et al., 2018 [123]; Kunkle et al., 2019 [62] 21 APP Antimicrobial peptide Kumar et al., 2016 [124]; Eimer et al., 2018 [125]; Jonsson et al., 2012 [126] zones into the brain parenchyma and subsequent T cell receptor (TCR) clonal expansion.”
BackgroundInhibition of protein aggregation and amyloid formation by small molecules
Doig, A. J., & Derreumaux, P. (2015) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2014.12.004 · Cited by 298
Sadleir, K. R., Kandalepas, P. C., Buggia-Prévot, V., Nicholson, D. A., Thinakaran, G., & Vassar, R. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1558-9 · Cited by 294
“1 3 [24]) AD by increasing or decreasing BACE1 cleavage of APP and Aβ production, respectively.”
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Neuroprotective Actions of Dietary Choline
Blusztajn, J., Slack, B., & Mellott, T. (2017) · Nutrients · doi:10.3390/nu9080815 · Cited by 293
“, non-carriers of the APOE ε4 allele [142–145] or individuals who inherit the rare APP A673T allele [146] may be somewhat protected.”
BackgroundChen, X.-Q., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 289
Monoaminergic neuropathology in Alzheimer’s disease
Šimić, G., Babić Leko, M., Wray, S., Harrington, C. R., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., de Silva, R., Di Giovanni, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.001 · Cited by 289
“A rare mutation in the APP gene that protects against AD and cognitive decline in the elderly without AD was also reported (Jonsson et al., 2012).”
Immunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284
Cuyvers, E., & Sleegers, K. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00127-7 · Cited by 284
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.075 · Cited by 275
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Neuronal hyperactivity--A key defect in Alzheimer’s disease?
Busche, M. A., & Konnerth, A. (2015) · BioEssays · doi:10.1002/bies.201500004 · Cited by 266
Neuroprotective Effects of Coffee Bioactive Compounds: A Review
Socała, K., Szopa, A., Serefko, A., Poleszak, E., & Wlaź, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010107 · Cited by 248
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Mielke, M. M., Vemuri, P., Lowe, V., Senjem, M. L., Gunter, J. L., Reyes, D., et al. (2015) · Brain · doi:10.1093/brain/awv283 · Cited by 254
“, 2014b) is that the decrease in frequency of A + N at ages beyond the mid70s is consistent with a specific mechanistic sequence in which amyloidosis induces neurodegeneration, an idea strongly supported by the genetics of Alzheimer’s disease (Goate et al., 1991; Levy-Lahad et al., 1995; Sherrington et al., 1995; Jons…”
BackgroundResultBis, J. C., Jian, X., Kunkle, B. W., Chen, Y., Hamilton-Nelson, K. L., Bush, W. S., Salerno, W. J., Lancour, D., Ma, Y., Renton, A. E., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0112-7 · Cited by 248
Self-citationRare variant association studies: considerations, challenges and opportunities
Auer, P. L., & Lettre, G. (2015) · Genome Medicine · doi:10.1186/s13073-015-0138-2 · Cited by 248
“By sequencing the whole genomes of 2,630 Icelanders, followed by imputation into large sets of GWAS data, novel associations between rare variants in APP and Alzheimer's disease and between rare variants in PDX1 and T2D were identified [39,75].”
MethodCellular Functions of the Amyloid Precursor Protein from Development to Dementia
van der Kant, R., & Goldstein, L. S. B. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.01.022 · Cited by 245
Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease
TCW, J., & Goate, A. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024539 · Cited by 242
Safiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236
“with the 40% decrease in Ab production because of a mutation that is protective for the development of AD (7).”
Assessment of the genetic variance of late-onset Alzheimer's disease
Ridge, P. G., Hoyt, K. B., Boehme, K., Mukherjee, S., Crane, P. K., Haines, J. L., Mayeux, R., Farrer, L. A., Pericak-Vance, M. A., Schellenberg, G. D., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.024 · Cited by 236
“dGertrude H. Sergievsky Center, Department of Neurology and the Taub Institute on Alzheimer’s”
Avrahami, L., Farfara, D., Shaham-Kol, M., Vassar, R., Frenkel, D., & Eldar-Finkelman, H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.409250 · Cited by 231
Emerging Concepts in Alzheimer's Disease
Vinters, H. V. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163927 · Cited by 235
Reversal of cognitive decline: A novel therapeutic program
Bredesen, D. E. (2014) · Aging · doi:10.18632/aging.100690 · Cited by 227
“Reducing this ratio, whether by affecting BACE (β-site APP cleaving enzyme) or other cleavage of APP, appears to mitigate the AD severity [7, 16, 17].”
BackgroundStop Alzheimer’s before it starts
McDade, E., & Bateman, R. J. (2017) · Nature · doi:10.1038/547153a · Cited by 230
Zhang, X., Tian, Y., Zhang, C., Tian, X., Ross, A. W., Moir, R. D., Sun, H., Tanzi, R. E., Moore, A., & Ran, C. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505420112 · Cited by 225
“It is well known that Aβ species, including soluble monomers, dimers, oligomers, and insoluble fibrils/aggregates and plaques, play a central role in the neuropathology of AD (2, 5).”
BackgroundDeveloping Therapeutic Antibodies for Neurodegenerative Disease
Yu, Y. J., & Watts, R. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0187-4 · Cited by 227
Self-citationKelleher, R. J., & Soiza, R. L. (2013) · Europe PMC (PubMed Central) · Cited by 277
Pharmacological chaperones stabilize retromer to limit APP processing
Mecozzi, V. J., Berman, D. E., Simoes, S., Vetanovetz, C., Awal, M. R., Patel, V. M., Schneider, R. T., Petsko, G. A., Ringe, D., & Small, S. A. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1508 · Cited by 216
Untangling Genetic Risk for Alzheimer’s Disease
Pimenova, A. A., Raj, T., & Goate, A. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.014 · Cited by 223
“APP-A673V, a LOAD mutant at the same amino acid that increas es Aβ production (60).”
BackgroundAn Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice
Sheline, Y. I., West, T., Yarasheski, K., Swarm, R., Jasielec, M. S., Fisher, J. R., Ficker, W. D., Yan, P., Xiong, C., Frederiksen, C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008169 · Cited by 223
“A recently discovered protective mutation in APP (A673T) has approximately the same magnitude of Ab-lowering effect as the citalopram effect in the current study, strengthening the argument for SSRIs as a potential AD prevention strategy (21).”
ResultKondo, T., Imamura, K., Funayama, M., Tsukita, K., Miyake, M., Ohta, A., Woltjen, K., Nakagawa, M., Asada, T., Arai, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.109 · Cited by 221
Oxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia
van der Flier, W. M., de Vugt, M. E., Smets, E. M. A., Blom, M., & Teunissen, C. E. (2023) · Nature Aging · doi:10.1038/s43587-023-00404-2 · Cited by 220
RNA interference in the era of nucleic acid therapeutics
Jadhav, V., Vaishnaw, A., Fitzgerald, K., & Maier, M. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02105-y · Cited by 207
Genetics of Alzheimer’s disease: where we are, and where we are going
Bellenguez, C., Grenier-Boley, B., & Lambert, J.-C. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.11.024 · Cited by 215
Axonal BACE1 dynamics and targeting in hippocampal neurons: a role for Rab11 GTPase
Buggia-Prévot, V., Fernandez, C. G., Riordan, S., Vetrivel, K. S., Roseman, J., Waters, J., Bindokas, V. P., Vassar, R., & Thinakaran, G. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-1 · Cited by 214
“Moreover, a single amino acid substitution adjacent to the BACE1 cleavage site of APP, which significantly reduces BACE1 cleavage and Aβ peptide generation in cultured cells, has been recently found to protect against disease onset as well as cognitive decline in the elderly without AD [10].”
BackgroundMouse Models of Alzheimer’s Disease
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.912995 · Cited by 213
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Mullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213
“against AD and also against cognitive decline in the elderly without AD [127].”
BackgroundBahn, G., Park, J.-S., Yun, U. J., Lee, Y. J., Choi, Y., Park, J. S., Baek, S. H., Choi, B. Y., Cho, Y. S., Kim, H. K., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819541116 · Cited by 210
“Bace1-deficient mice do not generate Aβ (2, 35), and the discovery of an APP mutation that reduces β-cleavage and protects against AD supports inhibition of BACE1 activity as a promising therapeutic strategy for AD (10, 36, 37).”
BackgroundA Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment
Das, B., & Yan, R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00613-7 · Cited by 201
Genetics of Alzheimer’s Disease
Chouraki, V., & Seshadri, S. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00005-6 · Cited by 209
Xu, Z., Jia, S., Wang, W., Yuan, Z., Jan Ravoo, B., & Guo, D.-S. (2019) · Nature Chemistry · doi:10.1038/s41557-018-0164-y · Cited by 204
May, P. C., Willis, B. A., Lowe, S. L., Dean, R. A., Monk, S. A., Cocke, P. J., Audia, J. E., Boggs, L. N., Borders, A. R., Brier, R. A., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4129-14.2015 · Cited by 206
“morphism in APP has been associated with reduced A production and apparent protection against AD and cognitive decline with aging (Jonsson et al., 2012).”
BackgroundInfluentialMorris, J. C., Aisen, P. S., Bateman, R. J., Benzinger, T. L., Cairns, N. J., Fagan, A. M., Ghetti, B., Goate, A. M., Holtzman, D. M., Klunk, W. E., et al. (2012) · Clinical Investigation · doi:10.4155/cli.12.93 · Cited by 208
Mitochondrial glutathione: Features, regulation and role in disease
Marí, M., Morales, A., Colell, A., García-Ruiz, C., Kaplowitz, N., & Fernández-Checa, J. C. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.10.018 · Cited by 204
Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease
Gallardo, G., & Holtzman, D. M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9358-8_16 · Cited by 198
Age and amyloid effects on human central nervous system amyloid‐beta kinetics
Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., Yarasheski, K., Sigurdson, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24454 · Cited by 200
“in genes that produce Ab have been shown to initiate AD in genetic studies of ADAD, and, more recently, a different mutation in the amyloid precursor protein (APP) gene has been shown to be a strongly protective factor.(10) Ab is a normal product of APP cleavage in the human central nervous system (CNS).”
BackgroundGyörgy, B., Lööv, C., Zaborowski, M. P., Takeda, S., Kleinstiver, B. P., Commins, C., Kastanenka, K., Mu, D., Volak, A., Giedraitis, V., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.03.007 · Cited by 190
“Interestingly, the extent of Ab reduction in non-mutated cells by WT gRNA slightly exceeds the 40% reduction in Ab levels that has been reported for the protective APP A673T mutation, originally identified in the Icelandic population.(23) However, in our cell-based model, the degree of Ab reduction will to some extent…”
BackgroundConvergent genetic and expression data implicate immunity in Alzheimer's disease
International Genomics of Alzheimer's Disease Consortium (IGAP), Jones, L., Lambert, J., Wang, L., Choi, S., Harold, D., Vedernikov, A., Escott‐Price, V., Stone, T., Richards, A., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.05.1757 · Cited by 199
“Recent findings show that there is at least one rare protective coding variant in APP seen in late-onset AD [28], and this signal may reflect this or other relatively rare variants.”
Maloney, J. A., Bainbridge, T., Gustafson, A., Zhang, S., Kyauk, R., Steiner, P., van der Brug, M., Liu, Y., Ernst, J. A., Watts, R. J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589069 · Cited by 197
Self-citationCherry, J. D., Liu, B., Frost, J. L., Lemere, C. A., Williams, J. P., Olschowka, J. A., & O’Banion, M. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0053275 · Cited by 198
“AD is characterized by a progressive cognitive decline over several years [9].”
BackgroundEarly-Onset Alzheimer’s Disease: What Is Missing in Research?
Ayodele, T., Rogaeva, E., Kurup, J. T., Beecham, G., & Reitz, C. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01090-y · Cited by 193
“While most mutations inAPP result in increased levels of Aβ aggregation and production [43], a protective APP variant (Icelandic mutation Ala673Thr) decreases Aβ levels by 40% [44] (Fig.”
BackgroundCheng, Y., Tian, D.-Y., & Wang, Y.-J. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00195-1 · Cited by 190
“A673T) in the APP gene results in a reduced risk for AD in an Icelandic elderly population [2].”
Raskin, J., Cummings, J., Hardy, J., Schuh, K., & Dean, R. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150701103107 · Cited by 188
“These researchers found a coding mutation in the APP gene that protects against AD [37].”
Bourdenx, M., Koulakiotis, N. S., Sanoudou, D., Bezard, E., Dehay, B., & Tsarbopoulos, A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.003 · Cited by 185
“Conversely, the ‘‘amyloidogenic’’ pathway is initiated by b-secretase (BACE1)-mediated cleavage, releases soluble APP b (sAPPb) to the extracellular space and leaves the 99-amino acid fragment of the C terminus (C99) in the membrane, to be subsequently cleaved by g-secretase complex and release Ab and APP intracellula…”
BackgroundInfluentialVisualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway
Das, U., Wang, L., Ganguly, A., Saikia, J. M., Wagner, S. L., Koo, E. H., & Roy, S. (2016) · Nature Neuroscience · doi:10.1038/nn.4188 · Cited by 192
“Recently, a search for low-frequency APP variants in whole genome sequencing data from Icelanders revealed a mutation that confers protection against AD [A673T or “Icelandic” mutation, henceforth called APP(Ice), 25 ].”
Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis
Cascella, R., & Cecchi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094914 · Cited by 185
“Jonsson and coworkers showed that the A672T mutation in the APP gene causes a decrease in the β-cleavage of APP, resulting in protection against AD [40].”
BackgroundRational designs of in vivo CRISPR-Cas delivery systems
Xu, C.-F., Chen, G.-J., Luo, Y.-L., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.005 · Cited by 184
Modeling Human Disease with Pluripotent Stem Cells: from Genome Association to Function
Merkle, F. T., & Eggan, K. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.05.016 · Cited by 185
“Alzheimer’s disease, lending credence to the notion that reducing the b cleavage of APP may protect against the disease (Jonsson et al., 2012).”
BackgroundOxidative stress involving changes in Nrf2 and ER stress in early stages of Alzheimer's disease
Mota, S. I., Costa, R. O., Ferreira, I. L., Santana, I., Caldeira, G. L., Padovano, C., Fonseca, A. C., Baldeiras, I., Cunha, C., Letra, L., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.03.015 · Cited by 183
“This hypothesis is supported, among other evidences, by the discovery of an APP mutation that decreases Aβ levels in vitro and protects against AD-associated cognitive decline [43].”
ResultActin dynamics and cofilin‐actin rods in alzheimer disease
Bamburg, J. R., & Bernstein, B. W. (2016) · Cytoskeleton · doi:10.1002/cm.21282 · Cited by 181
“In support of its causative role is the finding that individuals with the single A673T mutation in APP (the residue within the Ab peptide adjacent to the aspartyl protease (BACE) cleavage site) have a 40% reduction in amyloidogenic peptides and are strongly protected against AD [Jonsson et al., 2012].”
BackgroundAmyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Panza, F., Lozupone, M., Seripa, D., & Imbimbo, B. P. (2019) · Annals of Neurology · doi:10.1002/ana.25410 · Cited by 178
“In 2012, a gene mutation encoding for APP (A673T) was discovered to protect against AD and cognitive decline in normal elderly subjects, further strengthening the theory.(11) In late onset sporadic AD, accumulation is believed to be due to defective brain clearance of Aβ(12) and increased BACE activity.”
BackgroundTargeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation
Liao, F., Li, A., Xiong, M., Bien-Ly, N., Jiang, H., Zhang, Y., Finn, M. B., Hoyle, R., Keyser, J., Lefton, K. B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96429 · Cited by 178
“Also, a protective mutation in AD was recently described near the N-terminus of the secretase site in APP that results in decreased A production (4).”
BackgroundSelf-citationGenomic variants, genes, and pathways of Alzheimer's disease: An overview
Naj, A. C., Schellenberg, G. D., & for the Alzheimer's Disease Genetics Consortium (ADGC) (2017) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32499 · Cited by 179
“A whole-genome sequencing study examining genotypes of 1,795 Icelanders found a coding mutation in the APP gene (A673T) that protects against Alzheimer’s disease and cognitive decline in the elderly without Alzheimer’s disease [Jonsson et al., 2012].”
BackgroundScott, J. D., Li, S. W., Brunskill, A. P. J., Chen, X., Cox, K., Cumming, J. N., Forman, M., Gilbert, E. J., Hodgson, R. A., Hyde, L. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00307 · Cited by 174
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809316 · Cited by 177
“Inhibition of BACE-1 is a promising disease-modifying strategy for AD, validated by human genetics (Jonsson et al, 2012).”
BackgroundPathways to Alzheimer's disease
Hardy, J., Bogdanovic, N., Winblad, B., Portelius, E., Andreasen, N., Cedazo‐Minguez, A., & Zetterberg, H. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12192 · Cited by 176
Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers
Initiative, F. T. A. D. N., Shen, L., Thompson, P. M., Potkin, S. G., Bertram, L., Farrer, L. A., Foroud, T. M., Green, R. C., Hu, X., Huentelman, M. J., et al. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9262-z · Cited by 174
“A recent example (Jonsson et al. 2012a) comes from the analysis of whole genome sequencing (WGS) of roughly 1,800 Icelanders.”
Development and Mechanism of γ-Secretase Modulators for Alzheimer’s Disease
Crump, C. J., Johnson, D. S., & Li, Y.-M. (2013) · Biochemistry · doi:10.1021/bi400377p · Cited by 171
“It is noteworthy to mention a recent discovery showing that an APP mutation, which reduces Aβ production, protects against AD and age-related cognitive decline,(49) providing another line of support for the amyloid cascade hypothesis.”
BackgroundGrarup, N., Sulem, P., Sandholt, C. H., Thorleifsson, G., Ahluwalia, T. S., Steinthorsdottir, V., Bjarnason, H., Gudbjartsson, D. F., Magnusson, O. T., Sparsø, T., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003530 · Cited by 177
“Utilizing this resource many low frequency and rare causative sequence variants have recently been discovered that affect the risk of common diseases [22–26].”
BackgroundSelf-citationDetection and treatment of Alzheimer’s disease in its preclinical stage
Rafii, M. S., & Aisen, P. S. (2023) · Nature Aging · doi:10.1038/s43587-023-00410-4 · Cited by 160
Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy
Nalivaeva, N. N., & Turner, A. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14593 · Cited by 172
“5% of Icelandic people, is significantly more common in those >85‐year olds without AD or major cognitive decline (Jonsson et al., 2012).”
BackgroundThe genes associated with early-onset Alzheimer’s disease
Dai, M.-H., Zheng, H., Zeng, L.-D., & Zhang, Y. (2018) · Oncotarget · doi:10.18632/oncotarget.23738 · Cited by 167
“In the same amino acid position, another mutation (A673T) enriched in the Icelandic population is reported to be a protective variant [68].”
BackgroundLate-onset vs nonmendelian early-onset Alzheimer disease: A distinction without a difference?
Reitz, C., Rogaeva, E., & Beecham, G. W. (2020) · Neurology Genetics · doi:10.1212/nxg.0000000000000512 · Cited by 168
“19 Notably, a mutation at the same codon (Ala673Val) causes AD, but only in a recessive mode. e-14 The brain pathology of APP carriers is often accompanied by a signi fi cant level of cerebral amyloid angiopathy, which can lead to cerebral hemorrhage and stroke in carriers of APP duplications…”
BackgroundSecretase inhibitors for the treatment of Alzheimer's disease: Long road ahead
Kumar, D., Ganeshpurkar, A., Kumar, D., Modi, G., Gupta, S. K., & Singh, S. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.035 · Cited by 170
Chami, L., & Checler, F. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-52 · Cited by 168
“More recently, an additional genetic clue came from the observation that a novel mutation on βAPP that partly prevents its β-secretasemediated cleavage and thereby reducing Aβ load, indeed protected bearers from AD in an Icelanders cohort [8].”
BackgroundAdvancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes
Schreiber, S. L., Kotz, J. D., Li, M., Aubé, J., Austin, C. P., Reed, J. C., Rosen, H., White, E. L., Sklar, L. A., Lindsley, C. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.023 · Cited by 169
“the need for stabilizing a specific protein such as APP or ApoE to reduce levels of a posttranslational modification (Jonsson et al., 2012; Mahley and Huang, 2012).”
Atrián-Blasco, E., Gonzalez, P., Santoro, A., Alies, B., Faller, P., & Hureau, C. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.04.007 · Cited by 168
“Whereas A2T is protective against AD [51], A2V cause an early onset of disease at least on homozygous carriers [50], as it has been said in section 2.”
BackgroundInfluentialEndosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer’s disease
Small, S. A., Simoes-Spassov, S., Mayeux, R., & Petsko, G. A. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.08.003 · Cited by 168
BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease
Barão, S., Moechars, D., Lichtenthaler, S. F., & De Strooper, B. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.01.003 · Cited by 158
“The discovery of a rare b-secretase-cleavage-sparing variant of APP – APP-A673T [3] – that provides lifelong protection against AD further supported this hypothesis.”
BackgroundBellenguez, C., Charbonnier, C., Grenier-Boley, B., Quenez, O., Le Guennec, K., Nicolas, G., Chauhan, G., Wallon, D., Rousseau, S., Richard, A. C., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.07.001 · Cited by 166
“Finally, none of the ADES-FR participants carried the rare p.A673T APP variant which has been reported as protective (Jonsson et al., 2012).”
BackgroundRecent Progress in Alzheimer’s Disease Research, Part 2: Genetics and Epidemiology
Robinson, M., Lee, B. Y., & Hane, F. T. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161149 · Cited by 166
“A GWAS of 1,795 Icelanders resulted in the identification of a coding mutation (A673T) adjacent to the BACE1 cleavage site which was then shown to reduce the formation of A by 40% in vitro; in addition this mutation not only provides protection from AD but also protects against cognitive decline in the elderly [65].”
BackgroundIt's complicated: The relationship between sleep and Alzheimer's disease in humans
Lucey, B. P. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105031 · Cited by 168
Kawai, Y., Mimori, T., Kojima, K., Nariai, N., Danjoh, I., Saito, R., Yasuda, J., Yamamoto, M., & Nagasaki, M. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.68 · Cited by 163
Harris, S. S., Wolf, F., De Strooper, B., & Busche, M. A. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.005 · Cited by 161
Amyloid β-protein and beyond: the path forward in Alzheimer’s disease
Walsh, D. M., & Selkoe, D. J. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.02.003 · Cited by 157
Hung, C. O. Y., & Livesey, F. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.095 · Cited by 159
“Conversely, a protective mutation near the BACE-cleavage site in APP has been identified that reduces the risk of developing dementia (Jonsson et al., 2012).”
BackgroundLi, H., Liu, Y., Tian, D., Tian, L., Ju, X., Qi, L., Wang, Y., & Liang, C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112163 · Cited by 156
Self-citationAmyloid‐ß‐directed immunotherapy for Alzheimer's disease
Lannfelt, L., Relkin, N. R., & Siemers, E. R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12168 · Cited by 157
Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology
Shulman, J. M., Chen, K., Keenan, B. T., Chibnik, L. B., Fleisher, A., Thiyyagura, P., Roontiva, A., McCabe, C., Patsopoulos, N. A., Corneveaux, J. J., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2815 · Cited by 160
Alzheimer Disease and Its Growing Epidemic
Hickman, R. A., Faustin, A., & Wısnıewskı, T. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.009 · Cited by 205
“More than 30 coding APP mutations have been identified that usually result in an autosomal-dominant EOAD because of increased Ab production, shifts in synthesis of pathologic Ab1-42, or production of Ab that may have increased susceptibility to aggregation.(50) Of interest, not all APPmutations result in AD prepondera…”
BackgroundPassive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 155
McKenzie, A. T., Moyon, S., Wang, M., Katsyv, I., Song, W.-M., Zhou, X., Dammer, E. B., Duong, D. M., Aaker, J., Zhao, Y., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0219-3 · Cited by 154
“The role of BACE1 in OLs is of high relevance to AD, as mutations in the BACE1-cleaving region of APP have been associated with a decreased risk of AD [82], and β-secretase inhibitors intended to treat AD may have side-effects of myelin defects [83].”
BackgroundThe evolution of amidine-based brain penetrant BACE1 inhibitors
Oehlrich, D., Prokopcová, H., & Gijsen, H. J. M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.025 · Cited by 166
Metadata
- Authors
- Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., & Stefansson, K.
- Affiliations
- Genentech (US)
- deCODE Genetics (Iceland) (IS)
- University of Oslo (NO)
- Karolinska Institutet (SE)
- University of Helsinki (FI)
- ORCID
- Venue
- Nature
- Published
- 2012-07-11
- Volume
- 488
- Issue
- 7409
- Pages
- 96-99
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2154755614
- Cited by
- 1,738
- References
- 26
- Citations by year
- 2026: 56 · 2025: 72 · 2024: 93 · 2023: 94 · 2022: 70 · 2021: 120 · 2020: 134 · 2019: 107 · 2018: 134 · 2017: 145 · 2016: 155 · 2015: 166 · 2014: 173 · 2013: 154 · 2012: 60
- FWCI
- 119.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-102924, HL-102925, HL 103010, HL-102926)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, amyloid precursor protein, APP gene, protective genetic variants, cognitive decline in older adults, amyloid plaques, β-cleavage, amyloidogenic peptides, genetic risk, Icelandic population
- MeSH terms
- Aging, Alleles, Alzheimer Disease, Cognition, Cognition Disorders, Humans, Mutation, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Amyloid Precursor Protein Secretases, HEK293 Cells, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.